Developing and assessing cardiovascular biomarkers (Q37994308)

26 August 2017

Developing and assessing cardiovascular biomarkers (English)

1 reference

26 August 2017

1 reference

Christie M. Ballantyne

series ordinal

3

object named as

Christie M Ballantyne

1 reference

26 August 2017

Razvan T Dadu

1

1 reference

PubMed ID

22424430

26 August 2017

Vijay Nambi

series ordinal

2

1 reference

26 August 2017

27 January 2012

1 reference

26 August 2017

Translational Research

1 reference

26 August 2017

159

1 reference

26 August 2017

4

1 reference

26 August 2017

265-276

1 reference

Vascular biomarkers and surrogates in cardiovascular disease.

26 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.003

Role of biomarkers in developing new therapies for vascular disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.003

So, you want to look for biomarkers (introduction to the special biomarkers issue)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.003

Biomarkers of cardiovascular disease: molecular basis and practical considerations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.003

Exercise testing to predict outcome in patients with angina

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.003

The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.003

Criteria for evaluation of novel markers of cardiovascular risk: a scientific statement from the American Heart Association

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.003

Statistical evaluation of prognostic versus diagnostic models: beyond the ROC curve

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.003

Direct proinflammatory effect of C-reactive protein on human endothelial cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.003

Modulation of C-reactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.003

Endothelin antagonism and interleukin-6 inhibition attenuate the proatherogenic effects of C-reactive protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.003

C-reactive protein increases plasminogen activator inhibitor-1 expression and activity in human aortic endothelial cells: implications for the metabolic syndrome and atherothrombosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.003

Demonstration that C-reactive protein decreases eNOS expression and bioactivity in human aortic endothelial cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.003

A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.003

C-reactive protein-mediated low density lipoprotein uptake by macrophages: implications for atherosclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.003

Inflammation and atherosclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.003

C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.003

Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.003

C-reactive protein: eighty years from discovery to emergence as a major risk marker for cardiovascular disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.003

Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.003

Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.003

Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.003

Clinical implications of JUPITER (Justification for the Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin) in a U.S. population insights from the ARIC (Atherosclerosis Risk in Communities) study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.003

C-reactive protein in risk prediction of cardiovascular outcomes: Tehran Lipid and Glucose Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.003

The relationship between C-reactive protein and other cardiovascular risk factors in men and women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.003

Distribution and determinants of serum high-sensitive C-reactive protein in a population of young adults: The Cardiovascular Risk in Young Finns Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.003

Association between C-reactive protein, metabolic cardiovascular risk factors, obesity and oral contraceptive use in young adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.003

C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.003

Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.003

C-reactive protein is associated with subclinical epicardial coronary calcification in men and women: the Framingham Heart Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.003

Lack of association of C-reactive protein and coronary calcium by electron beam computed tomography in postmenopausal women: implications for coronary artery disease screening

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.003

High-sensitivity C-reactive protein is not associated with carotid intima-media progression: the carotid atherosclerosis progression study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.003

The association of C-reactive protein levels with carotid intima-media complex thickness and plaque formation in the general population

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.003

An assessment of incremental coronary risk prediction using C-reactive protein and other novel risk markers: the atherosclerosis risk in communities study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.003

Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.003

C-reactive protein modulates risk prediction based on the Framingham Score: implications for future risk assessment: results from a large cohort study in southern Germany

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.003

2010 ACCF/AHA Guideline for Assessment of Cardiovascular Risk in Asymptomatic Adults: Executive Summary

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.003

Using nontraditional risk factors in coronary heart disease risk assessment: U.S. Preventive Services Task Force recommendation statement

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.003

Meta-analysis of genome-wide association studies in >80 000 subjects identifies multiple loci for C-reactive protein levels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.003

Genetic Loci associated with C-reactive protein levels and risk of coronary heart disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.003

Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.003

Lp-PLA(2) as a marker of cardiovascular diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.003

Lipoprotein-associated phospholipase A2 and cardiovascular risk: state of the evidence and future directions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.003

Lipoprotein-associated phospholipase A2.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.003

Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.003

Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.003

Lipoprotein-associated phospholipase A2 adds to risk prediction of incident coronary events by C-reactive protein in apparently healthy middle-aged men from the general population: results from the 14-year follow-up of a large cohort from southern G

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.003

Lipoprotein-associated phospholipase A2 activity is associated with risk of coronary heart disease and ischemic stroke: the Rotterdam Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.003

Inflammatory biomarkers and the prediction of coronary events among people at intermediate risk: the EPIC-Norfolk prospective population study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.003

Lipoprotein-associated phospholipase A2 and high-sensitivity C-reactive protein improve the stratification of ischemic stroke risk in the Atherosclerosis Risk in Communities (ARIC) study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.003

Elevated Lp-PLA 2 Levels Add Prognostic Information to the Metabolic Syndrome on Incidence of Cardiovascular Events Among Middle-Aged Nondiabetic Subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.003

Lipoprotein-associated phospholipase A2 predicts 5-year cardiac mortality independently of established risk factors and adds prognostic information in patients with low and medium high-sensitivity C-reactive protein (the Ludwigshafen risk and cardio

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.003

Lipoprotein-associated phospholipase A2 and prognosis after myocardial infarction in the community

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.003

Lipoprotein-associated phospholipase A2 for early risk stratification in patients with suspected acute coronary syndrome: a multi-marker approach: the North Wuerttemberg and Berlin Infarction Study-II (NOBIS-II).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.003

Review of the evidence for the clinical utility of lipoprotein-associated phospholipase A2 as a cardiovascular risk marker

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.003

Eight genetic loci associated with variation in lipoprotein-associated phospholipase A2 mass and activity and coronary heart disease: meta-analysis of genome-wide association studies from five community-based studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.003

Lipoprotein-associated phospholipase A2: a potential new risk factor for coronary artery disease and a therapeutic target

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.003

Potent, orally active inhibitors of lipoprotein-associated phospholipase A(2): 1-(biphenylmethylamidoalkyl)-pyrimidones

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.003

Effects of the direct lipoprotein-associated phospholipase A(2) inhibitor darapladib on human coronary atherosclerotic plaque

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.003

Rationale and design of the dal-OUTCOMES trial: efficacy and safety of dalcetrapib in patients with recent acute coronary syndrome.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.003

Novel biomarkers in cardiovascular disease: update 2010.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.003

Myeloperoxidase-generated reactive nitrogen species convert LDL into an atherogenic form in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.003

Neutrophil infiltration of culprit lesions in acute coronary syndromes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.003

Widespread coronary inflammation in unstable angina

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.003

Macrophage myeloperoxidase regulation by granulocyte macrophage colony-stimulating factor in human atherosclerosis and implications in acute coronary syndromes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.003

Association between myeloperoxidase levels and risk of coronary artery disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.003

Serum myeloperoxidase levels are associated with the future risk of coronary artery disease in apparently healthy individuals: the EPIC-Norfolk Prospective Population Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.003

Myeloperoxidase serum levels predict risk in patients with acute coronary syndromes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.003

Prognostic value of myeloperoxidase in patients with chest pain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.003

Myeloperoxidase and C-reactive protein have combined utility for long-term prediction of cardiovascular mortality after coronary angiography

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.003

Effect of a short-term diet and exercise intervention on oxidative stress, inflammation, MMP-9, and monocyte chemotactic activity in men with metabolic syndrome factors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.003

Intracellular compartmentation of cardiac troponin T and its release kinetics in patients with reperfused and nonreperfused myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.003

Universal definition of myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.003

Prevalence and determinants of troponin T elevation in the general population

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.003

Relation between troponin T and the risk of subsequent cardiac events in unstable coronary artery disease. The FRISC study group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.003

Minimally elevated cardiac troponin T and elevated N-terminal pro-B-type natriuretic peptide predict mortality in older adults: results from the Rancho Bernardo Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.003

Persistent cardiac troponin I elevation in stabilized patients after an episode of acute coronary syndrome predicts long-term mortality

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.003

Prognostic value of very low plasma concentrations of troponin T in patients with stable chronic heart failure.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.003

A Sensitive Cardiac Troponin T Assay in Stable Coronary Artery Disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.003

Association of troponin T detected with a highly sensitive assay and cardiac structure and mortality risk in the general population

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.003

Association of serial measures of cardiac troponin T using a sensitive assay with incident heart failure and cardiovascular mortality in older adults.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.003

Cardiac troponin T measured by a highly sensitive assay predicts coronary heart disease, heart failure, and mortality in the Atherosclerosis Risk in Communities Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.003

Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.003

Natriuretic peptides: physiology, therapeutic potential, and risk stratification in ischemic heart disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.003

Plasma cardiac natriuretic peptide determination as a screening test for the detection of patients with mild left ventricular impairment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.003

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.003

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.003

National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: Clinical characteristics and utilization of biochemical markers in acute coronary syndromes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.003

Natriuretic peptides in elderly people with acute myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.003

Prognostic value of B-Type natriuretic peptides in patients with stable coronary artery disease: the PEACE Trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.003

Plasma natriuretic peptide levels and the risk of cardiovascular events and death

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.003

The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.003

B-type natriuretic peptides and cardiovascular risk: systematic review and meta-analysis of 40 prospective studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.003

Amino-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide: biomarkers for mortality in a large community-based cohort free of heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.003

Cardiovascular risk prediction by N-terminal pro brain natriuretic peptide and high sensitivity C-reactive protein is affected by age and sex.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.003

N-terminal pro-brain natriuretic peptide, C-reactive protein, and urinary albumin levels as predictors of mortality and cardiovascular events in older adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.003

Left ventricular dysfunction, natriuretic peptides, and mortality in an urban population

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.003

Plasma N-terminal fragments of natriuretic propeptides predict the risk of cardiovascular events and mortality in middle-aged men.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.003

Comparative impact of multiple biomarkers and N-Terminal pro-brain natriuretic peptide in the context of conventional risk factors for the prediction of recurrent cardiovascular events in the Heart Outcomes Prevention Evaluation (HOPE) Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.003

10.1016/J.TRSL.2012.01.003

7 January 2021

Identifiers

DOI

1 reference

26 August 2017

1 reference

PubMed ID

22424430